A director at Uniqa Insurance Group AG bought 10,000 shares at 7.322EUR and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
EQS-News: Flughafen Wien AG / Schlagwort(e): Quartals-/Zwischenmitteilung/9-Monatszahlen Flughafen Wien AG in Q1-3/2024: Positive Entwicklung bei Passagieren, Umsatz und Gewinn 14.11.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Flughafen Wien AG in Q1-3/2024: Positive Entwicklung bei Passagieren, Umsatz und Gewinn Q1-3/2024: Erfreulicher Passagierzuwachs von +9,1% auf 31,6 Mio. Passagiere in der Flughafen-Wien-Gruppe, am Standort Wien beträgt der Zuwachs +7,2% auf 24,1 Mio. Passagiere Trotz deutlich höherer Ko...
EQS-News: Flughafen Wien AG / Key word(s): Quarterly / Interim Statement/9 Month figures Flughafen Wien AG in Q1-3/2024: Positive development in passenger traffic, revenue and net profit 14.11.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Flughafen Wien AG in Q1-3/2024: Positive development in passenger traffic, revenue and net profit Q1-3/2024: Positive passenger growth of +9.1% to 31.6 million passengers in the Flughafen Wien Group, growth at the Vienna site of +7.2% to 24.1 million passengers Despite significantly...
Summary: Richter posted its Q3/24 results today morning. The Company matched the consensus for revenues at HUF 217bn, while the clean EBIT beat estimates by 3% as it came in at HUF 75bn. However, normal EBIT of HUF 64bn and net profit of HUF 37bn fell short of even our depressed expectation as an inventory impairment (HUF 9bn), provision (HUF 5bn) and an unrealized FX loss (HUF 20.8bn) dragged down earnings. The management fully reiterated its 2024 guidance. They continue to guide revenues ...
>Q2 2024-25 results below expectations - AT&S this morning reported its Q2 2024-25 results which beat expectations on sales/adjusted EBITDA but fell short on net profit and operating CF. Sales were € 451m, above the company-compiled consensus at € 423m. They were flat y-o-y and up 29% q-o-q. Adjusted EBITDA was € 127m, i.e. a margin of 28.1%, above the consensus at € 106m and 25%. Net profit was -€ 29m, below the consensus at -€ 10m, due notably to high start-up cos...
>Q2 2024-25 results below expectations - AT&S this morning reported its Q2 2024-25 results which beat expectations on sales/adjusted EBITDA but fell short on net profit and operating CF. Sales were € 451m, above the company-compiled consensus at € 423m. They were flat y-o-y and up 29% q-o-q. Adjusted EBITDA was € 127m, i.e. a margin of 28.1%, above the consensus at € 106m and 25%. Net profit was -€ 29m, below the consensus at -€ 10m, due notably to high start-up cos...
EQS-News: AT&S Austria Technologie & Systemtechnik AG / Schlagwort(e): Halbjahresergebnis/Quartals-/Zwischenmitteilung AT&S erwartet Umsatz auf Vorjahresniveau 31.10.2024 / 07:03 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. AT&S erwartet Umsatz auf Vorjahresniveau Umsatz im 2. Quartal 2024/25 mit 451 Mio. € um 29 % höher als im Vorquartal und auf dem gleichen Niveau wie im Vorjahresquartal (Q2 2023/24: 452 Mio. €; Q1 2024/25: 349 Mio. €) Ausblick für GJ 2024/25 aufgrund der Marktlage angepasst Ausblick für GJ 2026/27 bestä...
EQS-News: AT&S Austria Technologie & Systemtechnik AG / Key word(s): Half Year Results/Quarterly / Interim Statement AT&S expects revenue at prior-year level 31.10.2024 / 07:03 CET/CEST The issuer is solely responsible for the content of this announcement. AT&S expects revenue at prior-year level Revenue in Q2 2024/25 € 451 million, up 29% on Q1 2024/25 and at the same level as prior-year quarter (Q2 2023/24: € 452 million; Q1 2024/25: € 349 million) Outlook for FY 2024/25 adjusted due to market situation Outlook for FY 2026/27 confirmed Leoben – AT&S expects ...
Temenos, the European leader in core banking solutions with significant market share with Tier 3, 4 and 5 banks, faces structural challenges that impair its growth outlook: 1/ the reticence of major banking groups to renew their core banking system; 2/ fierce competition in the digital segment; and 3/ the slowdown in the launch pace for new neo-banks. Indeed, the group is set to scale back its medium-term targets at its CMD on 12 November. Moreover, the support for the stock offered b...
Temenos, leader européen des solutions Core Banking avec une part de marché significative auprès des banques Tiers 3, 4 et 5, fait face des défis structurels qui réduisent ses perspectives de croissance : 1/ la réticence des grands acteurs bancaires à renouveler leur Core banking system; 2/ la forte compétition sur le segment Digital et 3/ le ralentissement du rythme de lancement de nouvelles néo-banques. Aussi, le groupe devrait abaisser ses objectifs MT lors du CMD du 12 novembre. E...
>Underperformance rating reiterated following a PW raising questions about the investment case and liquidity risk - Target price adjusted to € 15 (vs € 19) - Yesterday, AT&S announced a new profit warning linked to a number of issues (pricing pressure, volatile orders from one customer, weakness of auto/industry, delay in the ramp-up of the AMD fab). We are lowering our EBITDA by ~10% over the next three years and adjusting our target price to €15 (DCF + multiple) vs ...
>Underperformance rating reiterated following a PW raising questions about the investment case and liquidity risk - Target price adjusted to € 15 (vs € 19) - Yesterday, AT&S announced a new profit warning linked to a number of issues (pricing pressure, volatile orders from one customer, weakness of auto/industry, delay in the ramp-up of the AMD fab). We are lowering our EBITDA by ~10% over the next three years and adjusting our target price to €15 (DCF + multiple) vs ...
>A fresh acceleration to worldwide semiconductor sales in August at +20.6% y-o-y (vs +18.7% in July) - Worldwide semiconductor sales in August 2024 were published by the WSTS (World Semiconductor Trade Statistics) with the usual one-month lag. On a three-month moving average, sales came to $ 53.1bn, ahead of our forecast of $ 52bn. This represents a sequential increase of 3.5% and +20.6% y-o-y, after +18.7% in July. At the regional level, sales from one year to the n...
>Nouvelle accélération de la croissance des ventes mondiales de semis en août à +20.6% yoy (vs +18.7% en juillet) - Les ventes mondiales de semiconducteurs d’août 2024 ont été publiées par WSTS (World Semiconductor Trade Statistics), avec (comme toujours) un mois de décalage. En données lissées (moyenne de 3 mois), elles ressortent à 53.1 Md$ au-dessus de notre prévision à 52 Md$. Il s’agit d’une hausse séquentielle de 3.5% et annuelle de 20.6% après 18.7% en juillet....
Last week we held our fourth ODDO BHF Iberian Forum. The event was fully virtual and took place on October 1 and 2. With 62 Iberian issuers, close to 200 institutional investors and c. 800 meetings, this is one of the largest dedicated Iberian conferences held this year. This note brings together 49 feedback documents, with 5 target price revisions (o/w 3 downward revisions) and a rating downgrade on Pharma Mar. The main subjects of debate were i/ the trend in final demand in the con...
Last week we held our fourth ODDO BHF Iberian Forum. The event was fully virtual and took place on October 1 and 2. With 62 Iberian issuers, close to 200 institutional investors and c. 800 meetings, this is one of the largest dedicated Iberian conferences held this year. This note brings together 49 feedback documents, with 5 target price revisions (o/w 3 downward revisions) and a rating downgrade on Pharma Mar. The main subjects of debate were i/ the trend in final demand in the con...
Last week we held our fourth ODDO BHF Iberian Forum. The event was fully virtual and took place on October 1 and 2. With 62 Iberian issuers, close to 200 institutional investors and c. 800 meetings, this is one of the largest dedicated Iberian conferences held this year. This note brings together 49 feedback documents, with 5 target price revisions (o/w 3 downward revisions) and a rating downgrade on Pharma Mar. The main subjects of debate were i/ the trend in final demand in the con...
Last week we held our fourth ODDO BHF Iberian Forum. The event was fully virtual and took place on October 1 and 2. With 62 Iberian issuers, close to 200 institutional investors and c. 800 meetings, this is one of the largest dedicated Iberian conferences held this year. This note brings together 49 feedback documents, with 5 target price revisions (o/w 3 downward revisions) and a rating downgrade on Pharma Mar. The main subjects of debate were i/ the trend in final demand in the con...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.